Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
141 participants
OBSERVATIONAL
2014-09-08
2015-11-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Indeed, there are no published data on this topic within the Italian context. The present explorative study aims at identifying the main problems with which patients affected by a Chronic Hematological Disease (CHD) deal when returning to everyday working life, factors associated with work reintegration and, finally, to understand the need for facilitators enhancing reintegration outcomes.
Results from this study will be also helpful to raise consciousness about the problem of reintegration into the labour market of workers with CHD and to call for awareness campaigns for the general public and health professionals.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Socio-psychological Factors Involved in the Hematopoietic Stem Cell Transplantation Process in People With Hemopathies
NCT03883672
Impact of Stem Cell Donation on Unrelated and Related Donors' Health.
NCT06905704
Behavioral Intervention For BMT/SCT Survivors
NCT00579917
Developing Self-Management Interventions After HCT
NCT03710031
Positive Psychology Intervention In HSCT
NCT05147311
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A number of economists have argued that there is a causal link between increasing inequality and the financial crisis. Evidence from different EU Member States shows that people who declare themselves as being permanently disabled are over-represented among people at risk of poverty or social exclusion compared to the whole population.
In Italy, in the second quarter of 2011, 6 million 556 thousand people aged 15-64 years (16.5% of the population of this age group) claimed to be suffering from one or more longstanding health problems or functional difficulties.
Health problems represent a barrier to the inclusion in the labour market. More than 50% of those suffering from more than one health problem or functional difficulties is inactive, this share decreases significantly among those who complain about one problem or difficulty (39.9%) and no problem (35.5%).
Among persons employed who complain of poor health conditions, about one in 10 may rely on one or more types of assistance in their place of work: availability of special equipment or workplace adaptations, personal service, special working arrangements. Among people who do not have a job, however, more than a quarter (26.6%) would need to receive at least one type of assistance in order to work.
People with long-term illnesses have an higher probability of leaving the workforce at an early age and people who continue to work despite health problems are likely to be less productive than healthy people. Thus, without a timely and appropriate reintegration, they may be less likely to return to work.
In this scenario it's of utmost importance to increase the overall capability to deliver targeted actions in order to be able to support people at risk of social -work exclusion.
Policy instruments being able to provide access to the labour market also play an important role, as well as measures in favor of education. Studies have shown several benefits associated with returning to work after cancer, including addressing financial needs, providing a distraction and an overall improvement in quality of life. Health professionals advice and support and the role of the employers in providing a sound workplace accommodation may play an important role in this regard but, on the other hand, a number of studies show an association between cancer survivorship and risk of unemployment.
The impact of returning to work after (or during) a long-term illness must be evaluated also from the perspective of the family and of the community. It could be very hard for partners and other relatives to conciliate their work duties with the task of taking care of the sick person - in terms of time and of mental strain. While laws usually allow for a number of measures to ease this issue, more information is often needed to workers and to employers.
The cost of a sick worker, from the viewpoint of the community, includes not only the cost of health care and rehabilitation but also the lost productivity of those who quit work and the cost linked to the possible impoverishment of the worker and her/his family for the years to come.
At present time there are no published studies that investigated these issues in patients with hematological malignancies in the Italian context. This explorative study aims at identifying the main problems that patients of Chronic Hematological Disease (CHD) deal when returning to everyday working life, factors associated with job reintegration and to understand the need for facilitators enhancing reintegration outcomes.
Results from this study will be also helpful in the effort of raising consciousness about the problem of reintegration in the labour market of workers with CHD and to call for awareness campaigns for the general public and health professionals.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study population
Patients diagnosed with Chronic Myeloid Leukaemia, Chronic Lymphocytic Leukaemia, Myelodysplastic Syndromes (low risk), Chronic Thrombocytopenia or Hodgkin Disease in complete remission, who have signed written informed consent according to ICH/EU/GCP and Italian laws, aged between 15 and 74 years old.
The study excludes non Italian speaking patients or unable to fully understand the study's forms.
Study questionnaire
Questionnaire based on work situation of enrolled patients.
SF-36 Questionnaire
Version 1.6
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Study questionnaire
Questionnaire based on work situation of enrolled patients.
SF-36 Questionnaire
Version 1.6
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signed written informed consent according to ICH/EU/GCP and national local laws.
* Age between 15 and 74 years old.
Exclusion Criteria
15 Years
74 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondazione Adecco per le Pari OpportunitÃ
UNKNOWN
Gruppo Italiano Malattie EMatologiche dell'Adulto
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Edoardo La Sala
Role: STUDY_CHAIR
GIMEMA Foundation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UO Ematologia con trapianto-Università degli Studi di Bari Aldo Moro
Bari, , Italy
Irccs Aou San Martino - Genova - Uo Ematologia E Trapianti
Genzano di Roma, , Italy
Ospedali Riuniti "Villa Sofia-Cervello"
Palermo, , Italy
U.O. Ematologia Clinica - Azienda USL di Pescara
Pescara, , Italy
Università degli Studi "Sapienza" - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia
Roma, , Italy
ULSS N.6 Osp. S. Bortolo
Vicenza, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
GIMEMA Foundation
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EMATO 0113
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.